Aziyo Biologics
Sep 17, 2020
Lilly’s COVID-19 antibody reduces hospitalization rate; Tiny biologic drug to combat COVID-19; Aziyo Biologics files for $57.5 M IPO; BMS exercises option on Obsidian’s CD40L cell therapy
Lilly links COVID-19 antibody to a reduce hospitalization rate Eli Lilly has linked its anti-SARS-CoV-2 antibody to a lower rate of hospitalization in patients lately diagnosed with mild to moderate cases of COVID-19. Nevertheless, two of the three doses, including the highest studied in the phase 2 trial, flunk...
Read More...
-Agonist.png "Toll-like Receptors Agonist")
